ReviewFrontiers in immunology2025
HIV cure research contributions from Africa in the last three decades.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Implications of HIV-1 Subtypes on Pathogenesis, Reservoirs and Cure Strategies.Current HIV/AIDS reports · 2026Review
- Tools to Quantify and Characterize the Persistent Reservoir in People with HIV-1: Focus on Non-B Subtypes.Viruses · 2026Review
- Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa.Frontiers in immunology · 2026Review
- HIV-2 infection as a comparative lens for functional HIV-1 remission.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: The HIV epidemic in Africa is characterized by extensive viral subtype diversity and human genetic heterogeneity which influence disease outcomes; amidst the co-morbidities that modulate HIV reservoirs and immune responses. This paper provides an overview of the quantity and spectrum of HIV cure research in context of the contributions made by African scientists toward HIV cure related research in Africa. Methods: Using a hybrid environmental scan, we searched the Treatment Action Group website to identify registered HIV cure-related observational and interventional studies between 1995-2024. To identify published papers related to HIV or SIV latency, we searched PubMed for articles with HIV or SIV in the title PLUS terms related to virus latency in the title or in medical subject headings (MeSH); and downloaded results in PubMed format in a text file. We used an R script which checked NCBI to identify articles which cited the original paper that first described the HIV reservoir in 1995, restricting to only those within the query result. This was repeated using loop functions until we obtained all articles directly or indirectly linked to the original paper. Results: Overall, we show an increasing trend of HIV cure-related observational and interventional studies globally; with the least number of studies in Africa. The PubMed query retrieved 7122 HIV cure-related published articles, as at 23 July 2024; of which 2820 were directly or indirectly linked to understanding the HIV reservoir. Of the 2916 articles with first author affiliation country determined, only 52 (0.02%) had affiliations from African institutions. Of the 1955 articles with last author affiliation country determined, only 43 (0.02%) had affiliations from institutions in Africa. The majority of articles with first or last authors from African institutes were descriptive clinical studies of HIV infection, with less than ten studies specifically addressing HIV latency. Conclusion: Scale up of HIV cure research in Africa remains critical to hasten achievement of the global goal of an end to the AIDS epidemic by 2030. There is a need to bridge the technical, infrastructural and technological divides and address constraints in funding and capacity; to promote discovery, characterization and application of promising innovative therapies including immunotherapies and cell and gene therapies towards attaining an effective, durable, affordable and scalable HIV cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.